Davis P
J Rheumatol. 1987 May;14 Spec No:94-7.
The size of the consumer market has resulted in an increasing number of antiinflammatory drugs available on prescription for osteoarthritis. Despite the development of newer chemical compounds, similarities in pharmacologic properties, efficacy in clinical trials, and toxicity profiles do not support a claim that any one drug is consistently better than another. Differences in pharmacokinetic profiles and formulations do allow for considerable flexibility in clinical therapeutics. Variabilities in drug action, effects on other organ systems, and drug interactions, particularly in the elderly, must always be considered when prescribing an individual medication. However, variability in patient response to individual drugs (both clinical benefit and toxicity) and the size of the clinical problem largely justify the number of nonsteroidal antiinflammatory drugs available.
消费者市场的规模导致用于骨关节炎的处方抗炎药数量不断增加。尽管有新的化合物问世，但药理特性、临床试验疗效和毒性特征方面的相似性并不支持任何一种药物始终优于另一种药物的说法。药代动力学特征和制剂方面的差异确实使临床治疗具有相当大的灵活性。在开具个体药物处方时，必须始终考虑药物作用的变异性、对其他器官系统的影响以及药物相互作用，尤其是在老年人中。然而，患者对个体药物的反应变异性（包括临床益处和毒性）以及临床问题的规模在很大程度上证明了现有非甾体抗炎药数量的合理性。
